Docosahexaenoic acid liposomes for targeting chronic inflammatory diseases and cancer: an in vitro assessment
Alaarg A, Jordan NY, Verhoef JJ, Metselaar JM, Storm G, Kok RJ
International journal of nanomedicine · 37 citas
Etiquetas de revisión
Financiación no declaradaSolo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio in vitro o de mecanismos (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas, más trabajo en animales o laboratorio
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2016-10-01 · Int J Nanomedicine · vol. Volume 11 · págs. 5027–5040
- Editorial
- Dove Medical Press
- Citado
- 59 citas · más que el 95% de estudios similares · 4.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 48 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC
- Áreas de investigación
- Fatty Acid Research and Health · Cholesterol and Lipid Metabolism · Eicosanoids and Hypertension Pharmacology
- Palabras clave
- Docosahexaenoic acid, Fish oil, Proinflammatory cytokine, Polyunsaturated fatty acid, Inflammation, Liposome, Immune system, Eicosapentaenoic acid, Cancer, Cancer cell, Cancer research, Pharmacology, Reactive oxygen species, Chemistry, Immunology, Medicine, Biology, Biochemistry, Fatty acid, Internal medicine
- MeSH
- monocytes, cells, cultured, macrophages, animals, humans, mice, carcinoma, squamous cell, breast neoplasms, inflammation, reactive nitrogen species, reactive oxygen species, docosahexaenoic acids, tumor necrosis factor-alpha, cytokines, liposomes, cell proliferation, oxidative stress, female, human umbilical vein endothelial cells, in vitro techniques
6 autores
- Amr Alaarg🇳🇱Utrecht University; University of Twente
- Nan Yeun Jordan🇳🇱Utrecht University; Pharmo Institute; University of Twente
- Johan J. F. Verhoef🇳🇱Utrecht University; Pharmo Institute
- Josbert M. Metselaar🇳🇱🇩🇪Utrecht University; Pharmo Institute; RWTH Aachen University; University of Twente
- Gert Storm🇳🇱Utrecht University; Pharmo Institute; University of Twente
- Robbert J. Kok🇳🇱Utrecht University; Pharmo Institute
Resumen
El texto original del estudio, en el idioma en que se publicó.
Inflammation, oxidative stress, and uncontrolled cell proliferation are common key features of chronic inflammatory diseases, such as atherosclerosis and cancer. ω3 polyunsaturated fatty acids (PUFAs; also known as omega3 fatty acids or fish oil) have beneficial effects against inflammation upon dietary consumption. However, these effects cannot be fully exploited unless diets are enriched with high concentrations of fish oil supplements over long periods of time. Here, a nanomedicine-based approach is presented for delivering effective levels of PUFAs to inflammatory cells. Nanoparticles are internalized by immune cells, and hence can adequately deliver bioactive lipids into these target cells. The ω3 FA docosahexaenoic acid was formulated into liposomes (ω-liposomes), and evaluated for anti-inflammatory effects in different types of immune cells. ω-Liposomes strongly inhibited the release of reactive oxygen species and reactive nitrogen species from human neutrophils and murine macrophages, and also inhibited the production of the proinflammatory cytokines TNFα and MCP1. Moreover, ω-liposomes inhibited tumor-cell proliferation when evaluated in FaDu head and neck squamous carcinoma and 4T1 breast cancer cells in in vitro cultures. We propose that ω-liposomes are a promising nanonutraceutical formulation for intravenous delivery of fish oil FAs, which may be beneficial in the treatment of inflammatory disorders and cancer.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.